Doximity, Inc. (NYSE:DOCS – Get Free Report) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, four have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $44.50.
DOCS has been the subject of several analyst reports. Canaccord Genuity Group upgraded Doximity from a “hold” rating to a “buy” rating and set a $34.00 target price for the company in a research report on Monday, February 9th. Zacks Research downgraded shares of Doximity from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 13th. Royal Bank Of Canada upgraded shares of Doximity to a “moderate buy” rating in a report on Thursday, January 8th. Needham & Company LLC raised shares of Doximity to a “moderate buy” rating in a report on Friday, February 6th. Finally, Truist Financial upgraded shares of Doximity from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 8th.
Get Our Latest Report on Doximity
Doximity Stock Down 2.5%
Doximity Company Profile
Doximity, trading as DOCS, operates a digital professional network and communications platform designed primarily for clinicians. Headquartered in San Francisco, the company connects physicians, nurse practitioners, physician assistants and other healthcare professionals, providing tools that streamline clinical communication, telehealth delivery and access to specialty-specific medical information. Its platform is positioned as a professional hub where clinicians manage their workflows, stay current with medical news and collaborate securely with peers.
The company’s offerings include secure messaging and video telehealth capabilities that enable clinicians to consult with patients and colleagues while protecting patient information.
Further Reading
- Five stocks we like better than Doximity
- The gold chart Wall Street is terrified of…
- This makes me furious
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.
